| 2018 | | A study of clinicopathologic factors as indicators for early prediction of suboptimal debulking surgery after neoadjuvant chemotherapy in advanced ovarian cancer | 공태욱, 백지흠, 손주혁, 유희석, 장석준 |
| 2016 | | Clinical impact of high mobility group box 1 protein in epithelial ovarian cancer | 백지흠 |
| 2024 | | Comparison of Outcomes in Bowel Resections by Gynecologic Oncologists Versus General Surgeons During Maximal Cytoreductive Surgery for Advanced Ovarian Cancer: Gynecologic Oncology Research Investigators Collaboration Study (GORILLA-3006) | 공태욱, 김지연, 손주혁, 장석준 |
| 2019 | | Comparison of posterior rectal dissection techniques during rectosigmoid colon resection as part of cytoreductive surgery in patients with epithelial ovarian cancer: Close rectal dissection versus total mesorectal excision | 공태욱, 백지흠, 손주혁, 유희석, 장석준 |
| 2023 | | Cost-effectiveness of hyperthermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III-IV ovarian cancer from a randomized controlled phase III trial in Korea (KOV-HIPEC-01) | 장석준 |
| 2024 | | Extra-abdominal cytoreductive techniques in ovarian cancer: how far can (should) we go? | 장석준 |
| 2023 | | Hyperthermic Intraperitoneal Chemotherapy After Interval Cytoreductive Surgery for Patients With Advanced-Stage Ovarian Cancer Who Had Received Neoadjuvant Chemotherapy | 장석준 |
| 2023 | | Optimum selection criteria for secondary cytoreductive surgery in patients with recurrent epithelial ovarian cancer: A multicenter study from the Gynecologic Oncology Research Investigators coLLaborAtion group (GORILLA-3001) | 공태욱, 손주혁, 장석준 |
| 2019 | | Perioperative outcomes of extensive bowel resection during cytoreductive surgery in patients with advanced ovarian cancer | 공태욱, 백지흠, 손주혁, 유희석, 장석준 |
| 2017 | | Porta hepatis debulking procedures as part of primary cytoreductive surgery for advanced ovarian cancer | 손주혁, 유희석, 장석준 |
| 2019 | | Practice patterns of surgery for advanced ovarian cancer: analysis from international surveys | 장석준 |
| 2022 | | Quality of life outcomes from the randomized trial of hyperthermic intraperitoneal chemotherapy following cytoreductive surgery for primary ovarian cancer (KOV-HIPEC-01) | 장석준 |
| 2021 | | Rectosigmoid resection by gynecologic oncologists versus colorectal surgeons: As long as it catches the mouse, does the color of the cat matter? | 장석준 |
| 2018 | | Risk factors for septic adverse events and their impact on survival in advanced ovarian cancer patients treated with neoadjuvant chemotherapy and interval debulking surgery | 공태욱, 백지흠, 손주혁, 유희석, 장석준 |
| 2015 | | Role of aggressive surgical cytoreduction in advanced ovarian cancer. | 장석준 |
| 2023 | | Significance of cholecystectomy in cytoreductive surgery for advanced ovarian cancer | 공태욱, 김지연, 손주혁, 장석준 |
| 2024 | | Surgery for Recurrent Epithelial Ovarian Cancer | 장석준 |
| 2022 | | Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial | 장석준 |
| 2016 | | Total parietal peritonectomy with en bloc pelvic resection for advanced ovarian cancer with peritoneal carcinomatosis | 장석준 |
